Answer
Jul 10, 2025 - 01:44 PM
Safinamide, marketed under the brand name Xadago, is classified as a monoamine oxidase B (MAO-B) inhibitor. It is used as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease to help manage symptoms by increasing and prolonging the effects of dopamine in the brain. This classification helps in reducing "off" time and improving motor function in individuals with Parkinson's disease.
